Oraquick Ebola News Today

OraSure Technologies (NASDAQ:OSUR – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report released on Wednesday. Separately, Evercore ISI cut their target price on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating on the stock in a report on Thursday, April […]

StockNews.com upgraded shares of OraSure Technologies (NASDAQ:OSUR – Free Report) from a hold rating to a buy rating in a report issued on Wednesday. Separately, Evercore ISI cut their price target on shares of OraSure Technologies from $7.00 to $6.50 and set an in-line rating on the stock in a report on Thursday, April 4th. […]

OraSure Technologies (NASDAQ:OSUR – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk. Valuation & Earnings This table compares OraSure […]

OraSure Technologies (Nasdaq:OSUR) announced today that received a government contract to develop a second-generation Ebola diagnostic.

The firm will update its Ebola rapid antigen test that was authorized by the US Food and Drug Administration in 2019.

Brokerages expect OraSure Technologies, Inc. (NASDAQ:OSUR – Get Rating) to announce ($0.14) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for OraSure Technologies’ earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.07). OraSure Technologies reported earnings per share of ($0.02) in the same […]

OraSure Technologies (NASDAQ:OSUR – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays […]

Analysts expect OraSure Technologies, Inc. (NASDAQ:OSUR – Get Rating) to announce $64.74 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for OraSure Technologies’ earnings, with the highest sales estimate coming in at $68.30 million and the lowest estimate coming in at $62.22 million. OraSure Technologies posted […]

Analysts forecast that OraSure Technologies, Inc. (NASDAQ:OSUR – Get Rating) will announce sales of $64.74 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for OraSure Technologies’ earnings, with the lowest sales estimate coming in at $62.22 million and the highest estimate coming in at $68.30 million. OraSure […]

Shares of OraSure Technologies, Inc. (NASDAQ:OSUR – Get Rating) have been given an average recommendation of “Hold” by the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the […]